No Yes Ok

Archive

EQT LS portfolio company Nouscom Raises €67.5 million ($72 million) in Oversubscribed Series C Financing Round Tuesday, November 14th, 2023
New specialist European and US life sciences investors join existing investors to enable Nouscom to continue advancing the clinical development of its portfolio of neoantigen cancer vaccines to key clinical proof of c [...]
EQT Life Sciences Co-Leads VectorY’s €129 Million ($138 Million) Tuesday, November 14th, 2023
  Round co-led by EQT Life Sciences and Forbion    Series A financing will support clinical development of the lead program in amyotrophic lateral sclerosis (ALS) and preclinical development of pip [...]
EQT Life Sciences invests in $61 Million financing of AstronautX Monday, October 16th, 2023
Amsterdam, The Netherlands, October 16, 2023 - EQT Life Sciences is happy to announce an investment from the LSP Dementia Fund into AstronauTx Ltd. (“AstronauTx” or “the Company”), a UK based biotech compan [...]
EQT Life Sciences Leads €54 Million Upsized Financing in MinervaX Thursday, October 12th, 2023
EQT Life Sciences leads investment in MinervaX with OrbiMed also joining as a new investor   The financing will advance the development of MinervaX’s maternal vaccine against Group B Streptococcus and he [...]
EQT Life Sciences largest investor in Agomab’s USD 100 million Series C financing Wednesday, October 11th, 2023
-       EQT Life Sciences invests together with other new investors Fidelity Management & Research Company, Canaan and Dawn Biopharma, a platform controlled by KKR   -       Proceeds will support [...]
ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023 Tuesday, April 18th, 2023
[...]
EQT Life Sciences closes Dementia Fund at the hard cap Wednesday, March 29th, 2023
The LSP Dementia Fund has held its final close at approximately EUR 260 million, at the hard cap and above its original target fund size of EUR 100 million Investors include the Alzheimer’s Association, th [...]
EQT Life Sciences Co-leads $88 Million Series B Financing in QurAlis Thursday, March 9th, 2023
Proceeds will advance a pipeline of precision medicines against neurodegenerative diseases. Funding will support the clinical development of two therapeutic product candidates for ALS.   AMSTERDAM [...]
EQT Life Sciences participates in €32 Million financing round of Xeltis Tuesday, February 21st, 2023
Xeltis receives series D2 investments to advance Xeltis’ aXess vascular access graft into pivotal clinical trials.   Amsterdam, The Netherlands – 21 February, 2023, EQT Life Sciences today announced that [...]


2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

EQT LS portfolio company Nouscom Raises €67.5 million ($72 million) in Oversubscribed Series C Financing Round Tuesday, November 14th, 2023
New specialist European and US life sciences investors join existing investors to enable Nouscom to continue advancing the clinical development of its portfolio of neoantigen cancer vaccines to key clinical proof of c [...]
EQT Life Sciences Co-Leads VectorY’s €129 Million ($138 Million) Tuesday, November 14th, 2023
  Round co-led by EQT Life Sciences and Forbion    Series A financing will support clinical development of the lead program in amyotrophic lateral sclerosis (ALS) and preclinical development of pip [...]
EQT Life Sciences invests in $61 Million financing of AstronautX Monday, October 16th, 2023
Amsterdam, The Netherlands, October 16, 2023 - EQT Life Sciences is happy to announce an investment from the LSP Dementia Fund into AstronauTx Ltd. (“AstronauTx” or “the Company”), a UK based biotech compan [...]
EQT Life Sciences Leads €54 Million Upsized Financing in MinervaX Thursday, October 12th, 2023
EQT Life Sciences leads investment in MinervaX with OrbiMed also joining as a new investor   The financing will advance the development of MinervaX’s maternal vaccine against Group B Streptococcus and he [...]
EQT Life Sciences largest investor in Agomab’s USD 100 million Series C financing Wednesday, October 11th, 2023
-       EQT Life Sciences invests together with other new investors Fidelity Management & Research Company, Canaan and Dawn Biopharma, a platform controlled by KKR   -       Proceeds will support [...]
ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023 Tuesday, April 18th, 2023
[...]
EQT Life Sciences closes Dementia Fund at the hard cap Wednesday, March 29th, 2023
The LSP Dementia Fund has held its final close at approximately EUR 260 million, at the hard cap and above its original target fund size of EUR 100 million Investors include the Alzheimer’s Association, th [...]
EQT Life Sciences Co-leads $88 Million Series B Financing in QurAlis Thursday, March 9th, 2023
Proceeds will advance a pipeline of precision medicines against neurodegenerative diseases. Funding will support the clinical development of two therapeutic product candidates for ALS.   AMSTERDAM [...]
EQT Life Sciences participates in €32 Million financing round of Xeltis Tuesday, February 21st, 2023
Xeltis receives series D2 investments to advance Xeltis’ aXess vascular access graft into pivotal clinical trials.   Amsterdam, The Netherlands – 21 February, 2023, EQT Life Sciences today announced that [...]


2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund